arrow
S

Saurabh Dahiya

stanford university
H指数:28
被引数:5,433

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Superior Chronic Graft-versus-Host Disease–Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation

与他克莫司/甲氨蝶呤相比,在骨髓清除性HLA匹配的异基因造血细胞移植中,移植后环磷酰胺具有更优的慢性移植物抗宿主病无病生存率

2026-03-250
OAAI
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

利萨库肽马瑞卢赛尔在复发或难治性大B细胞淋巴瘤患者中的真实世界结局

Blood
IF23.1
2026-03-050
OA
Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients

基于ZUMA-1试验队列4对CAR-T细胞接受者细胞因子释放综合征和免疫效应细胞相关神经毒性综合征的应对策略的实践经验

2026-01-010
PRE
Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas

淋巴瘤患者接受桥接放疗前CAR-T细胞治疗期间的局部反应和治疗动力学

2025-12-010
PRE
NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma

NKTR-255可增强CD19 CAR-T在复发/难治性大B细胞淋巴瘤患者中的完全缓解率。

2025-08-110
OAAI
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy

自体干细胞加强治疗后BCMA-CAR T细胞治疗患者的IEC-HS致命复发

2025-05-140
OA
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma

lisocabtagene maraleucel和mosunetuzumab治疗第三线或更后线复发或难治性滤泡性淋巴瘤的疗效和安全性匹配调整间接比较

2025-03-050
OA
Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

CAR T细胞疗法、自体干细胞移植和标准癌症疗法后治疗相关性髓系肿瘤的队列比较

BLOOD
IF23.1
2024-11-050
PRE
Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

真实世界中,接受阿西美妥昔单抗(axicabtagene ciloleucel)治疗复发或难治性(r/r)大B细胞淋巴瘤(LBCL)的美国患者中,细胞因子释放综合征和神经事件的趋势及其管理模式:一项CIBMTR报告

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

利索卡巴肽马瑞克塞尔(liso-cel)在复发或难治性(R/R)滤泡性淋巴瘤(FL)患者(pts)中的2年随访:超越FL研究

BLOOD
IF23.1
2024-11-050
PRE
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment
2024-09-090
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study (JUL, 10.1038/s41591-024-02986-9, 2024)
2024-07-094
OAAI
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-speci fi c expansion and toxicity
2024-06-258
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024-06-039
OAAI